# US WorldMeds

Source: https://onco.cc/companies/us-worldmeds/  
OnCo record `us-worldmeds` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

US WorldMeds is a private Louisville company that took over the engineered T-cell therapies Tecelra and lete-cel from Adaptimmune in 2025 and sells eflornithine (Iwilfin) for maintenance in high-risk neuroblastoma. Whether a small private firm can sustain T-cell manufacturing for a rare sarcoma is the open question.

## Summary

US WorldMeds, a private company based in Louisville, Kentucky, took over the cell therapies Tecelra and lete-cel from Adaptimmune in 2025 and markets eflornithine, sold as Iwilfin, for neuroblastoma. It acquired Adaptimmune's assets afamitresgene autoleucel and letetresgene autoleucel in August 2025, with a biologics licence application for lete-cel committed by the end of 2026, and Iwilfin was approved in December 2023 for maintenance in high-risk neuroblastoma. OnCo links it to sarcomas and paediatric neuroblastoma, to all three drug records, and to bottlenecks on rare and paediatric cancers without markets and the lack of incentive to repurpose cheap drugs. Whether a small private company can sustain engineered T-cell manufacturing for a rare sarcoma is the open question. Each product has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- Also known as: USWM, LLC; US WorldMeds; USWM
- HQ: Louisville, KY
- Type: pharma
- Website: https://www.usworldmeds.com

## Sources

- Official website: https://www.usworldmeds.com

## Connected records

- cancers: [High-risk neuroblastoma](https://onco.cc/cancers/neuroblastoma-high-risk/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Afamitresgene autoleucel](https://onco.cc/drugs/afamitresgene-autoleucel/), [Eflornithine (DFMO)](https://onco.cc/drugs/eflornithine/), [Letetresgene autoleucel](https://onco.cc/drugs/letetresgene-autoleucel/)
- bottlenecks: [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/), [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)

---
JSON: https://onco.cc/api/v1/entities/us-worldmeds.json